Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen

被引：0
|
作者：
Yan, Jing-He
Taylor, Amanda
Clough, Timothy
Burmeister-Getz, Elise
Pazdirkova, Marketa
Russo, Cesare
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4135023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4135023
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine
    Mittur, Aravind
    Madanick, Ryan
    Langlois, Melanie
    Boyd, Brooks
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (07): : 887 - 898
  • [42] Effect of hepatic impairment on the pharmacokinetics of ripretinib.
    Li, Xiaoyan
    Psoinos, Charles M.
    Shelton, Mark Joel
    Abane, Farida
    Matson, Mark A.
    Oberstein, Samuel
    Ruiz-Soto, Rodrigo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16031 - E16031
  • [43] Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron
    James Dickinson
    Michaelene Lewand
    Taiji Sawamoto
    Walter Krauwinkel
    Marloes Schaddelee
    James Keirns
    Virginie Kerbusch
    Selina Moy
    John Meijer
    Donna Kowalski
    Richard Morton
    Kenneth Lasseter
    Dennis Riff
    Viera Kupčová
    Marcel van Gelderen
    Clinical Drug Investigation, 2013, 33 : 11 - 23
  • [44] The effect of hepatic impairment on the pharmacokinetics of zolmitriptan (Zomig™)
    French, SB
    Dixon, RM
    Kemp, JV
    Sellers, MV
    LeClerc, V
    Delvaux, M
    Ratureau, J
    NEUROLOGY, 1998, 50 (04) : A266 - A267
  • [45] Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
    Small, David S.
    Zhang, Wei
    Royalty, Jane
    Cannady, Ellen A.
    Downs, Delyn
    Ortega, Demetrio
    Suico, Jeffrey G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (05) : 563 - 572
  • [46] Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics
    Bauman, John W.
    Vincent, Carolyn T.
    Peng, Bin
    Wire, Mary B.
    Williams, Daphne D.
    Park, Jung Wook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 739 - 750
  • [47] Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron
    Dickinson, James
    Lewand, Michaelene
    Sawamoto, Taiji
    Krauwinkel, Walter
    Schaddelee, Marloes
    Keirns, James
    Kerbusch, Virginie
    Moy, Selina
    Meijer, John
    Kowalski, Donna
    Morton, Richard
    Lasseter, Kenneth
    Riff, Dennis
    Kupcova, Viera
    van Gelderen, Marcel
    CLINICAL DRUG INVESTIGATION, 2013, 33 (01) : 11 - 23
  • [48] Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
    David S. Small
    Wei Zhang
    Jane Royalty
    Ellen A. Cannady
    Delyn Downs
    Demetrio Ortega
    Jeffrey G. Suico
    European Journal of Clinical Pharmacology, 2016, 72 : 563 - 572
  • [49] EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF LURASIDONE.
    Chiu, Y.
    Gu, K.
    Poola, N.
    Brearley, C.
    Sarubbi, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S32 - S32
  • [50] Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
    Linh Nguyen
    Holland, Jaymes
    Ramies, David
    Mamelok, Richard
    Benrimoh, Natacha
    Ciric, Sabrina
    Marbury, Thomas
    Preston, Richard A.
    Heuman, Douglas M.
    Gavis, Edith
    Lacy, Steven
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (09): : 1130 - 1140
12345